Abstract
Background: The incidence of opioid-related overdose deaths has been rising for 30 years and has been further exacerbated amidst the COVID-19 pandemic. Naloxone can reverse opioid overdose, lower death rates, and enable a transition to medication for opioid use disorder. Though current formulations for community use of naloxone have been shown to be safe and effective public health interventions, they rely on bystander presence. We sought to understand the preferences and minimum necessary conditions for wearing a device capable of sensing and reversing opioid overdose among people who regularly use opioids.
Methods: We conducted a combined cross-sectional survey and semi-structured interview at a respite center, shelter, and syringe exchange drop-in program in Philadelphia, Pennsylvania, USA during the COVID-19 pandemic in August and September 2020. The primary aim was to explore the proportion of participants who would use a wearable device to detect and reverse overdose. Preferences regarding designs and functionalities were collected via a questionnaire with items having Likert-based response options and a semi-structured interview intended to elicit feedback on prototype designs. Independent variables included demographics, opioid use habits, and previous experience with overdose.
Results: A total of 97 adults with an opioid-use history of at least 3 months were interviewed. A majority of survey participants (76%) reported a willingness to use a device capable of detecting an overdose and automatically administering a reversal agent upon initial survey. When reflecting on the prototype, most respondents (75.5%) reported that they would wear the device always or most of the time. Respondents indicated discreetness and comfort as important factors that increased their chance of uptake. Respondents suggested that people experiencing homelessness and those with low tolerance for opioids would be in greatest need of the device.
Conclusions: The majority of people sampled with a history of opioid use in an urban setting were interested in having access to a device capable of detecting and reversing an opioid overdose. Participants emphasized privacy and comfort as the most important factors influencing their willingness to use such a device.
Introduction
The opioid crisis has escalated for three decades, with the COVID-19 pandemic further increasing overdose mortality. While naloxone (Narcan) is a highly effective reversal agent, its success in community settings is currently limited by the necessity of a bystander. In Philadelphia’s Kensington neighborhood—a national epicenter of the crisis—75–80% of fatal overdoses occur when individuals are alone. To bridge this "using alone" gap, researchers explored the feasibility of a wearable medical device capable of autonomously sensing respiratory depression and administering a reversal agent.
Methods
This study employed a mixed-methods approach, combining a cross-sectional survey with semi-structured interviews. Conducted in Philadelphia between August and September 2020, the research engaged 97 adults with at least a three-month history of opioid use. Participants were recruited from syringe exchange programs, shelters, and respite centers.
The researchers utilized non-functional prototypes of varying sizes to elicit tactile feedback on form factor and comfort. Data collection focused on demographics, opioid use habits, and preferences for device functionality and wearability.
Results
The study population was characterized by high-risk factors, including significant rates of housing insecurity and long-term opioid use. As shown in the demographic data, over 82% of participants used opioids daily, and 71% had personally experienced a prior overdose.
Participant Willingness and Preferences
Initial survey results indicated that 76% of participants were willing to use a device capable of detecting and reversing an overdose. After interacting with prototypes, 75.5% reported they would wear the device "always or most of the time."
Key functional preferences included:
- Vital Sign Monitoring: 77% interest.
- Overdose Sensing: 73% interest.
- Medical Alerting: 71% interest.
Design and Form Factor
Miniaturization and discreetness were identified as critical adoption factors. Approximately 89% of participants preferred the smallest prototype. Wrist-based designs (watches or bracelets) were the most favored (73–77% likelihood of use), while highly visible options like nasal cannulas (13%) or glasses (26%) were largely rejected.
Discussion
The Bystander Paradox and Privacy
A significant finding was the "Bystander Paradox": participants were least interested in devices that required a second person for intervention (e.g., a device that simply holds naloxone for a bystander to use). This preference for automated, closed-loop systems reflects a lack of trust in strangers and the reality of isolated drug use. Furthermore, discreetness was viewed as a safety feature to avoid law enforcement attention or potential robbery.
Concerns and Technical Challenges
While the life-saving potential was widely recognized, some participants expressed concern regarding "false positives"—the accidental injection of naloxone during a non-fatal high, which would induce immediate withdrawal. Engineering challenges remain in developing algorithms that can accurately distinguish between a deep high and a fatal overdose while minimizing these false positives.
Limitations
The study's findings are primarily applicable to high-density urban environments with established harm reduction infrastructures. The high proportion of participants experiencing homelessness or living in shelters (approx. 69%) may also influence preferences compared to "functional" users who use opioids in private residences.
Conclusion
There is substantial interest among people who use opioids in Philadelphia for a wearable device that can autonomously detect and reverse overdoses. For such technology to be successful, developers must prioritize user privacy, comfort, and independence from bystander intervention.
Summary updated